Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGI-110 in Japanese Patients with AML
NCT02293993Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of guadecitabine in acute myeloid leukemia (AML) (4 cohorts), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jan 2015; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02293993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293993.